Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Long-Term Investments (2018 - 2022)

Arcturus Therapeutics Holdings' Long-Term Investments history spans 5 years, with the latest figure at $131000.0 for Q1 2022.

  • For Q1 2022, Long-Term Investments fell 89.5% year-over-year to $131000.0; the TTM value through Mar 2022 reached $131000.0, down 89.5%, while the annual FY2021 figure was $515000.0, N/A changed from the prior year.
  • Long-Term Investments reached $131000.0 in Q1 2022 per ARCT's latest filing, down from $515000.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $1.2 million in Q1 2021 to a low of $100000.0 in Q1 2020.
  • Average Long-Term Investments over 5 years is $493111.1, with a median of $303000.0 recorded in 2019.
  • Peak YoY movement for Long-Term Investments: surged 1148.0% in 2021, then plummeted 89.5% in 2022.
  • A 5-year view of Long-Term Investments shows it stood at $288000.0 in 2018, then decreased by 8.68% to $263000.0 in 2019, then crashed by 61.98% to $100000.0 in 2020, then surged by 415.0% to $515000.0 in 2021, then tumbled by 74.56% to $131000.0 in 2022.
  • Per Business Quant, the three most recent readings for ARCT's Long-Term Investments are $131000.0 (Q1 2022), $515000.0 (Q4 2021), and $670000.0 (Q3 2021).